CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01116648
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:17.623866+00:00
Published At: 2020-07-22T00:00:00+00:00
Record Updated At: 2026-03-05
Results Posted At: 2020-07-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Fallopian Tube Carcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-05"
protocolSection.identificationModule.nctId: "NCT01116648"
protocolSection.identificationModule.officialTitle: "Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-07-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.